

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
Washington, D.C. 20231

In re PATENT APPLICATION of
Inventors **Keith D. ALLEN et al.**
Appin. No.: **09/816,790**
Filed: **March 22, 2001**

Title: **TRANSGENIC MICE CONTAINING
SULFOTRANSFERASE GENE DISRUPTIONS**



RECEIVED

JUL 25 2002

TECH CENTER 1600/2900

Group Art Unit: **1636**
Examiner: **Gian, Celine X.**
Docket/Order #: **R-855**
Deposit Acct: **50-1271**
Customer #: **26619**

Date: **July 11, 2002**

COPY OF PAPERS
ORIGINALLY FILED

AMENDMENT TRANSMITTAL

Sir:

Please file the enclosed amendment in the above-identified application. The signature below is to be treated as the signature to the enclosure in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity previously claimed	Claims remaining	Highest # paid for	Present Extra	Small Entity	Add'l Fee	Fee Code
2. Total Claims	14	minus 33	0	x \$9. =	+ 0	203
3. Independent Claims	7	minus 14	0	x 42. =	+ 0	202
4. If amendment enters multiple dependent claim(s) for the first..... add				+ \$140. =	+ 0	204
5. Original due date: June 11, 2002						
6. Petition is hereby made to extend the due date to cover the date this response is filed, for which the requisite fee is enclosed				1 mo \$55 2mos \$200 3mos \$460 =	55.00	215 216 217
7. Enter any previous extension fee paid and (subtract)-						
8. Total fee for extension of time: +						
9. If Terminal Disclaimer is enclosed, add Rule 20(d) official fee.....				+ \$55. =	+ 0	248
10. If IDS enclosed requires Official Fee, add				+ \$180. =	+ 0	126
or if Rule 97(d) Petition, add				+ \$130. =	+ 0	122
11. After-Final Request Fee per Rules 129(a) and 17(r).....				+ \$370. =	+ 0	246
12. No. of additional inventions for examination per Rule 129(b):.....			ea	x \$370. =	+ 0	249
13. Petition fee for					+ 0	
TOTAL FEE: <input checked="" type="checkbox"/> CHARGE AUTHORIZATION <input type="checkbox"/> ENCLOSED =						\$ 55.00

Charge Statement: The Commissioner is hereby authorized to charge any missing or insufficient fees relative to this application, or credit any overpayment, to our Account/Order Nos. above, for which purpose a duplicate copy of this sheet is enclosed.

DELTAGEN, INC.

740 Bay Road
Redwood City, CA 94063
Tel: (650) 569-5100
Fax: (650) 569-5280


Marlette A. Lapiz
MARLETTE A. LAPIZ, Reg. No. 44,202

CERTIFICATE OF MAILING Under 37 C.F.R. 1.8

I certify that this paper and listed enclosures are being deposited with the U.S. Post Office as First Class Mail with sufficient postage in an envelope addressed to: Commissioner for Patents, BOX AMENDMENT, Washington, D.C. 20231 on July 11, 2002

Deborah A. Mojarro

Deborah A. Mojarro



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE JUL 20 2002

Application of: Keith D. ALLEN

Group Art Unit: 1636

TECH CENTER 1600/2900

Serial No.: 09/816,790

Examiner: Qian, Celine X.

Filed: March 22, 2001

Attorney Docket No.: R-855

For: TRANSGENIC MICE CONTAINING SULFOTRANSFERASE GENE DISRUPTIONS

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 11, 2002 in connection with the above-identified application, Applicants request entry and consideration of the following amendments and remarks. Applicants submit concurrently herewith a Petition for the Extension of Time under 37 CFR 1.136(a) for response to the Office Action for a period of one month from June 11, 2002 up to and including July 11, 2002.

THE AMENDMENTS

In the claims:

✓
Please cancel claims 1-10 and 17-21.

Please add new claims 26-39 as follows:

26. (New) A targeting construct comprising:

- (a) a first polynucleotide sequence homologous to a first region of a sulfotransferase gene;
- (b) a second polynucleotide sequence homologous to a second region of a sulfotransferase gene; and
- (c) a selectable marker located between the first polynucleotide sequence and the second polynucleotide sequence,

B1

C

07/23/2002 SDENBOR1 00000015 501271 09816790

01 FC:215 55.00 CH